Resistance to Targeted Therapies in Breast Cancer / edited by Jenifer R. Prosperi

Contributor(s):

Prosperi, Jenifer R [HerausgeberIn]

Resource type: Ressourcentyp: Buch (Online)Book (Online)Language: English Series: Resistance to Targeted Anti-Cancer Therapeutics ; 16 | SpringerLink Bücher | Springer eBook Collection Biomedical and Life SciencesPublisher: Cham : Springer, 2017Description: Online-Ressource (XV, 184 p. 12 illus. in color, online resource)ISBN:

9783319701424

Subject(s):

Additional physical formats: 9783319701417 | Erscheint auch als: 978-3-319-70141-7 Druck-Ausgabe | Printed edition: 9783319701417 LOC classification:

RC261-271

NLM classification:

WP 870

DOI: DOI: 10.1007/978-3-319-70142-4Online resources:

Summary: We present an in-depth description of resistance to targeted therapies in breast cancer. Targeted therapies discussed here include those used to treat ER+ or Her2+ breast cancers (i.e., Tamoxifen or trastuzumab) or those targeting signaling pathways aberrantly activated in triple negative breast cancer (i.e., EGFR and Wnt signaling). We have also provided an overview of standard of care as an introduction into the importance of targeted therapy. It is our hope that this volume gives an insight into the landscape of breast cancer treatment, the challenges of targeted therapy, and a glimpse into the future of breast cancer therapy.Summary: Invasive Breast Cancer Therapy 2017: How Well Are We Hitting The Target? -- Resistance to HER2-targeted therapy -- Endocrine Resistance and Breast Cancer Stem Cells - The Inflammatory Connection That Could Lead to New and Improved Therapy Outcomes -- EGFR Resistance -- Targeting FGFR for the treatment of breast cancer -- Targeted Therapies in Breast Cancer -- Future paradigm of breast cancer resistance and treatmentPPN: PPN: 1658624858Package identifier: Produktsigel: ZDB-2-SBL

Holdings ( 0 )

No physical items for this record